Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer
Abstract BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials. Therefore, we hypothesized that the...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Cancer Immunology, Immunotherapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00262-025-04005-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850206384535109632 |
|---|---|
| author | Eunyoung Tak Hye-In An Amy Sinyoung Lee Kyuyoung Han Jiwan Choi Hyung-don Kim Yong Sang Hong Sun Young Kim Eun Kyung Choi Jeong Eun Kim Tae Won Kim |
| author_facet | Eunyoung Tak Hye-In An Amy Sinyoung Lee Kyuyoung Han Jiwan Choi Hyung-don Kim Yong Sang Hong Sun Young Kim Eun Kyung Choi Jeong Eun Kim Tae Won Kim |
| author_sort | Eunyoung Tak |
| collection | DOAJ |
| description | Abstract BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials. Therefore, we hypothesized that the treatment would be effective against BRAF-mutant colorectal cancer. In this study, we assessed the efficacy of combining immune checkpoint inhibitors with BRAF and/or MEK inhibitors in BRAF-mutant colorectal cancers. We treated BRAF V600E colorectal cancer cells HT-29 and SNU-1235 with encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) and assessed the degrees of MAPK inhibition, JAK/STAT inhibition, cell viability, apoptosis, and the expression of antigen presenting machinery. We also inoculated HT-29 cells into mice and treated them with an immune checkpoint inhibitor (durvalumab), encorafenib, and binimetinib for 4 weeks. We found that treatment with BRAF inhibitor, MEK inhibitor, or their combination led to significant tumor growth reduction, along with the MAPK and JAK/STAT pathway inhibition, antigen presenting machinery induction, and cytotoxic T cell activation. Our study demonstrates the potential effectiveness of combining immune checkpoint inhibitors with BRAF or MEK inhibitors for BRAF-mutated colorectal cancers. |
| format | Article |
| id | doaj-art-eaf8542d93c04d52921cbdf2f6a8cd6b |
| institution | OA Journals |
| issn | 1432-0851 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Springer |
| record_format | Article |
| series | Cancer Immunology, Immunotherapy |
| spelling | doaj-art-eaf8542d93c04d52921cbdf2f6a8cd6b2025-08-20T02:10:50ZengSpringerCancer Immunology, Immunotherapy1432-08512025-03-0174511410.1007/s00262-025-04005-3Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancerEunyoung Tak0Hye-In An1Amy Sinyoung Lee2Kyuyoung Han3Jiwan Choi4Hyung-don Kim5Yong Sang Hong6Sun Young Kim7Eun Kyung Choi8Jeong Eun Kim9Tae Won Kim10Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of MedicineDepartment of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of MedicineDepartment of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of MedicineDepartment of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of MedicineDepartment of Convergence Medicine, Asan Medical Institute of Convergence Science and Technology (AMIST), Asan Medical Center, University of Ulsan College of MedicineDepartment of Oncology, University of Ulsan College of MedicineDepartment of Oncology, University of Ulsan College of MedicineDepartment of Oncology, University of Ulsan College of MedicineDepartment of Radiation Oncology, Asan Preclinical Evaluation Center for Cancer TherapeutiX, Asan Medical Center, University of Ulsan College of MedicineDepartment of Oncology, University of Ulsan College of MedicineDepartment of Oncology, University of Ulsan College of MedicineAbstract BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials. Therefore, we hypothesized that the treatment would be effective against BRAF-mutant colorectal cancer. In this study, we assessed the efficacy of combining immune checkpoint inhibitors with BRAF and/or MEK inhibitors in BRAF-mutant colorectal cancers. We treated BRAF V600E colorectal cancer cells HT-29 and SNU-1235 with encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) and assessed the degrees of MAPK inhibition, JAK/STAT inhibition, cell viability, apoptosis, and the expression of antigen presenting machinery. We also inoculated HT-29 cells into mice and treated them with an immune checkpoint inhibitor (durvalumab), encorafenib, and binimetinib for 4 weeks. We found that treatment with BRAF inhibitor, MEK inhibitor, or their combination led to significant tumor growth reduction, along with the MAPK and JAK/STAT pathway inhibition, antigen presenting machinery induction, and cytotoxic T cell activation. Our study demonstrates the potential effectiveness of combining immune checkpoint inhibitors with BRAF or MEK inhibitors for BRAF-mutated colorectal cancers.https://doi.org/10.1007/s00262-025-04005-3BRAF V600EBRAF inhibitorMEK inhibitorAnti-PD-L1Immunotherapy |
| spellingShingle | Eunyoung Tak Hye-In An Amy Sinyoung Lee Kyuyoung Han Jiwan Choi Hyung-don Kim Yong Sang Hong Sun Young Kim Eun Kyung Choi Jeong Eun Kim Tae Won Kim Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer Cancer Immunology, Immunotherapy BRAF V600E BRAF inhibitor MEK inhibitor Anti-PD-L1 Immunotherapy |
| title | Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer |
| title_full | Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer |
| title_fullStr | Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer |
| title_full_unstemmed | Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer |
| title_short | Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer |
| title_sort | antitumor effects of immunotherapy combined with braf and mek inhibitors in braf v600e metastatic colorectal cancer |
| topic | BRAF V600E BRAF inhibitor MEK inhibitor Anti-PD-L1 Immunotherapy |
| url | https://doi.org/10.1007/s00262-025-04005-3 |
| work_keys_str_mv | AT eunyoungtak antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT hyeinan antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT amysinyounglee antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT kyuyounghan antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT jiwanchoi antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT hyungdonkim antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT yongsanghong antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT sunyoungkim antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT eunkyungchoi antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT jeongeunkim antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer AT taewonkim antitumoreffectsofimmunotherapycombinedwithbrafandmekinhibitorsinbrafv600emetastaticcolorectalcancer |